Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer
作者： Benjamin Solomon , Peter Savas , Brett Hughes
DOI: 10.3978/J.ISSN.2072-1439.2013.08.52
关键词:
摘要: Advances in the treatment of non-small cell lung cancer (NSCLC) over last decade have predominantly involved development therapies directed at molecular targets such as mutations epidermal growth factor receptor (EGFR) or rearrangements anaplastic lymphoma kinase (ALK) gene. Other been discovered low frequency, with multiple agents approved for these rare subtypes. The tumour microenvironment has also provided opportunities targeting angiogenesis and host immune response. This review will provide an overview current targeted NSCLC promising approaches on horizon.
amegroups.com参考文章(150)
_ _, Non–Small Cell Lung Cancer Journal of The National Comprehensive Cancer Network. ,vol. 6, pp. 228- 269 ,(2010) , 10.6004/JNCCN.2008.0021
Robert Pirker, Jose R Pereira, Aleksandra Szczesna, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Ihor Vynnychenko, Keunchil Park, Chih-Teng Yu, Valentyn Ganul, Jae-Kyung Roh, Emilio Bajetta, Kenneth O'Byrne, Filippo de Marinis, Wilfried Eberhardt, Thomas Goddemeier, Michael Emig, Ulrich Gatzemeier, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. The Lancet. ,vol. 373, pp. 1525- 1531 ,(2009) , 10.1016/S0140-6736(09)60569-9
Jun Kurai, Hiroki Chikumi, Kiyoshi Hashimoto, Kosuke Yamaguchi, Akira Yamasaki, Takanori Sako, Hirokazu Touge, Haruhiko Makino, Miyako Takata, Masanori Miyata, Masaki Nakamoto, Naoto Burioka, Eiji Shimizu, Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines Clinical Cancer Research. ,vol. 13, pp. 1552- 1561 ,(2007) , 10.1158/1078-0432.CCR-06-1726
Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li, Yerong Hu, Zhiping Tan, Matthew Stokes, Laura Sullivan, Jeffrey Mitchell, Randy Wetzel, Joan MacNeill, Jian Min Ren, Jin Yuan, Corey E. Bakalarski, Judit Villen, Jon M. Kornhauser, Bradley Smith, Daiqiang Li, Xinmin Zhou, Steven P. Gygi, Ting-Lei Gu, Roberto D. Polakiewicz, John Rush, Michael J. Comb, Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer Cell. ,vol. 131, pp. 1190- 1203 ,(2007) , 10.1016/J.CELL.2007.11.025
Hiromasa Yamamoto, Hisayuki Shigematsu, Masaharu Nomura, William W. Lockwood, Mitsuo Sato, Naoki Okumura, Junichi Soh, Makoto Suzuki, Ignacio I. Wistuba, Kwun M. Fong, Huei Lee, Shinichi Toyooka, Hiroshi Date, Wan L. Lam, John D. Minna, Adi F. Gazdar, PIK3CA Mutations and Copy Number Gains in Human Lung Cancers Cancer Research. ,vol. 68, pp. 6913- 6921 ,(2008) , 10.1158/0008-5472.CAN-07-5084
Giorgio V. Scagliotti, Ihor Vynnychenko, Keunchil Park, Yukito Ichinose, Kaoru Kubota, Fiona Blackhall, Robert Pirker, Rinat Galiulin, Tudor-Eliade Ciuleanu, Oleksandr Sydorenko, Mircea Dediu, Zsolt Papai-Szekely, Natividad Martinez Banaclocha, Sheryl McCoy, Bin Yao, Yong-jiang Hei, Francesco Galimi, David R. Spigel, International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1 Journal of Clinical Oncology. ,vol. 30, pp. 2829- 2836 ,(2012) , 10.1200/JCO.2011.41.4987
Vicki Leigh Keedy, Sarah Temin, Mark R. Somerfield, Mary Beth Beasley, David H. Johnson, Lisa M. McShane, Daniel T. Milton, John R. Strawn, Heather A. Wakelee, Giuseppe Giaccone, American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy Journal of Clinical Oncology. ,vol. 29, pp. 2121- 2127 ,(2011) , 10.1200/JCO.2010.31.8923
Justin F. Gainor, Anna M. Varghese, Sai-Hong Ignatius Ou, Sheheryar Kabraji, Mark M. Awad, Ryohei Katayama, Amanda Pawlak, Mari Mino-Kenudson, Beow Y. Yeap, Gregory J. Riely, A. John Iafrate, Maria E. Arcila, Marc Ladanyi, Jeffrey A. Engelman, Dora Dias-Santagata, Alice T. Shaw, ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer Clinical Cancer Research. ,vol. 19, pp. 4273- 4281 ,(2013) , 10.1158/1078-0432.CCR-13-0318
Fabrice Barlesi, Helene Blons, Michele Beau-Faller, Isabelle Rouquette, L'houcine Ouafik, Jean Mosser, Jean-Philippe Merlio, Pierre Paul Bringuier, Philippe Jonveaux, Cedric Le Marechal, Marc G. Denis, Frederique Madeleine Penault-Llorca, Didier Debieuvre, Jean-Charles Soria, Jacques Cadranel, Julien Mazieres, Pascale Missy, Franck Morin, Frederique Nowak, Gerard Zalcman, , Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). Journal of Clinical Oncology. ,vol. 31, pp. 8000- 8000 ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.8000
Marina Chiara Garassino, Olga Martelli, Anna Bettini, Irene Floriani, Elena Copreni, Calogero Lauricella, Monica Ganzinelli, Mirko Marabese, Massimo Broggini, Silvio Veronese, Giorgio Gherardi, Flavia Longo, Maria Agnese Fabbri, Maurizio Tomirotti, Oscar Alabiso, Maria Giuseppa Sarobba, Roberto Labianca, Silvia Marsoni, Gabriella Farina, Alberto Scanni, TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR. Journal of Clinical Oncology. ,vol. 30, pp. LBA7501- LBA7501 ,(2012) , 10.1200/JCO.2012.30.15_SUPPL.LBA7501